Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463945 | 0.95 | PTPN11 (0.54) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL25727131 | 0.95 | PTPN11 (0.54) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL25727149 | 0.95 | PTPN11 (0.54) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL30463958 | 0.95 | PTPN11 (0.54) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL6788341 | 0.88 | PTPN11 (0.50) | PTPN11DDB1CRBNL3MBTL1 | |
| SCHEMBL23789542 | 0.87 | PTPN11 (0.58) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL31070817 | 0.86 | PTPN11 (0.57) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL30433066 | 0.86 | PTPN11 (0.57) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL6789803 | 0.86 | PTPN11 (0.48) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL31017536 | 0.86 | PTPN11 (0.48) | PTPN11DDB1CRBNADRA2ADRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706885-B2 | HYDROGENATION OF PROTECTED 2,5-DI-(3'-AMINOPROP-1-YNYL) PYRIDINES AND DEPROTECTING TO FORM 2,5-DI-(3'-AMINOPROPYL)-PYRIDINES | MERCK & CO., INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030004353-A1 | Process for preparing integrin antagonist intermediates | MERCK SHARP & DOHME CORP. | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004353-A1 | Process for preparing integrin antagonist intermediates | ITGA5, ITGAV, ITGA2 | PTPN11 3250/4885DDB1 4703/4885CRBN 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.